Skip to main content

Advertisement

SpringerLink
Log in

Nesfatin-1 and other hormone alterations in polycystic ovary syndrome

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Polycystic ovary syndrome (PCOS) is commonly characterised by obesity, insulin resistance (IR), hyperandrogenemia and hirsutism. Nesfatin-1 a recently discovered hormone, acts upon energy balance, glucose metabolism, obesity and probably gonadal functions. This study was to evaluate the circulating levels of nesfatin-1 in patients with PCOS (n = 30) and in age and body mass index (BMI)-matched controls (n = 30). PCOS patients had significantly lower levels of nesfatin-1 (0.88 ± 0.36 ng/mL) than healthy controls (2.22 ± 1.14 ng/mL). PCOS patients also had higher gonadotropin and androgen plasma concentrations, Ferriman–Gallwey scores, blood glucose levels and a homeostasis model of assessment-IR index (HOMA-IR) index than in healthy women. Correlation tests in PCOS subjects detected a negative correlation between nesfatin-1 levels and BMI, fasting blood glucose, insulin levels and a HOMA-IR index. Lower nesfatin-1 concentration may plays a very important role in the development of PCOS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

17-Αhp:

17 Alpha hydroxyprogesterone

AS:

Androstenedione

BMI:

Body mass index

CSF:

Cerebrospinal fluid

CV:

Coefficient of variance

DHEA-S:

Dehydroepiandrosterone sulphate

DM:

Diabetes mellitus

E2 :

Estradiol

EDTA:

Ethylenediaminetetraacetic acid

FABP4:

Fatty acid binding protein

FBG:

Fasting blood glucose

FG:

Ferriman–Gallwey

FSH:

Follicle-stimulating hormone

FSI:

Fasting serum insulin

HDL:

High density lipoprotein

HOMA-IR:

Homeostasis model of assessment-insulin resistance index

IGF-1:

Insulin-like growth factor

IR:

Insulin resistance

KIU:

Kallikrein inactivation unit

LDL:

Low density lipoprotein

LH:

Luteinizing hormone

LMD:

Last menstrual date

PCOS:

Polycystic ovary syndrome

PRL:

Prolactin

SHBG:

Sex-hormone binding globulin

TSH:

Thyroid-stimulating hormone

TT:

Total testosterone

VLDL:

Very low density lipoprotein

WHR:

Waist-hip circumference ratio

References

  1. L. Speroff, Anovulation and polycystic ovary. In Clinical Gynecologic Endocrinology and Infertility, eds. by L. Speroff, M.A. Fritz MA, 6th edn. (Lippincott Williams and Wilkins, Philadelphia, 2005), pp. 465–491

  2. Z.E. Hopkinson, N. Sattar, R. Fleming, I.A. Greer, Polycystic ovarian syndrome: the metabolic syndrome comes to gynecology. BMJ 317, 329–332 (1998)

    Article  PubMed  CAS  Google Scholar 

  3. R. Azziz, K.S. Woods, R. Reyna, T.J. Key, E.S. Knochenhauer, B.O. Yildiz, The prevalence and feature of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 89, 2745–2749 (2004)

    Article  PubMed  CAS  Google Scholar 

  4. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, revised consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19, 41–47 (2004)

  5. D.A. Ehrmann, Polycystic ovary syndrome. N. Engl. J. Med. 352, 1223–1236 (2005)

    Article  PubMed  CAS  Google Scholar 

  6. H.J. Teede, S.K. Hutchison, S. Zoungas, The management of insulin resistance in polycystic ovary syndrome. Trends Endocrinol. Metab. 18, 273–279 (2007)

    Article  PubMed  CAS  Google Scholar 

  7. R. Hamburg, Management of polycystic ovary syndrome in adolescence. Rev. Gynecol. Pract. 4, 148–155 (2004)

    Article  Google Scholar 

  8. H. Jia, L. Yu, X. Guo, W. Gao, Z. Jiang, Associations of adiponectin gene polymorphisms with polycystic ovary syndrome: a meta-analysis. Endocrine. (2012, in press)

  9. B. Dilbaz, E. Ozkaya, M. Cinar, E. Cakir, S. Dilbaz, Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes. Endocrine 39, 272–277 (2011)

    Article  PubMed  CAS  Google Scholar 

  10. W. Hu, J. Qiao, Expression and regulation of adipocyte fatty acid binding protein in granulosa cells and its relation with clinical characteristics of polycystic ovary syndrome. Endocrine 40, 196–202 (2011)

    Article  PubMed  CAS  Google Scholar 

  11. S. Palomba, A. Falbo, T. Russo, A. Tolino, F. Orio, F. Zullo, Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes. Fertil. Steril. 94, 1805–1811 (2010)

    Article  PubMed  Google Scholar 

  12. I. Oh, H. Shimizu, T. Satoh, S. Okada, S. Adachi, K. Inoue, H. Eguchi, M. Yamamoto, T. Imaki, K. Hashimoto, T. Tsuchiya, T. Monden, K. Horiguchi, M. Yamada, M. Mori, Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 443, 709–712 (2006)

    Article  Google Scholar 

  13. D. García-Galiano, V.M. Navarro, J. Roa, F. Ruiz-Pino, M.A. Sánchez-Garrido, R. Pineda, J.M. Castellano, M. Romero, E. Aguilar, F. Gaytán, C. Diéguez, L. Pinilla, M. Tena-Sempere, The anorexigenic europeptide, nesfatin-1, is indispensable for normal puberty onset in the female rat. J. Neurosci. 30, 7783–7792 (2010)

    Article  PubMed  Google Scholar 

  14. Y. Su, J. Zhang, Y. Tang, F. Bi, J.N. Liu, The novel function of nesfatin-1: anti-hyperglycemia. Biochem. Biophys. Res. Commun. 391, 1039–1042 (2010)

    Article  PubMed  CAS  Google Scholar 

  15. Q.C. Li, H.Y. Wang, X. Chen, H.Z. Guan, Z.Y. Jiang, Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul. Pept. 159, 72–77 (2010)

    Article  PubMed  CAS  Google Scholar 

  16. S. Aydin, The presence of the peptides apelin, ghrelin and nesfatin-1 in the human breast milk, and the lowering of their levels in patients with gestational diabetes mellitus. Peptides 31, 2236–2240 (2010)

    Article  PubMed  CAS  Google Scholar 

  17. M. Aslan, O. Celik, N. Celik, I. Turkcuoglu, E. Yilmaz, A. Karaer, Y. Simsek, E. Celik, S. Aydin, Cord blood nesfatin-1 and apelin-36 levels in gestational diabetes mellitus. Endocrine. (2011, in press)

  18. E. Carmina, A.M. Campagna, R.A. Lobo, A 20-year follow-up of young women with polycystic ovary syndrome. Obstet. Gynecol. 119, 263–269 (2012)

    Article  PubMed  Google Scholar 

  19. D. Dewailly, P. Pigny, B. Soudan, S. Catteau-Jonard, C. Decanter, E. Poncelet, A. Duhamel, Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism. J. Clin. Endocrinol. Metab. 95, 4399–4405 (2010)

    Article  PubMed  CAS  Google Scholar 

  20. D. Dewailly, H. Gronier, E. Poncelet, G. Robin, M. Leroy, P. Pigny, A. Duhamel, S. Catteau-Jonard, Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum. Reprod. 26, 3123–3129 (2011)

    Article  PubMed  CAS  Google Scholar 

  21. S. Aydin, Discovery of ghrelin hormone: research and clinical applications. Turk. J. Biochem. 32, 76–89 (2007)

    Google Scholar 

  22. L. Ibanez, N. Potau, A. Carrascosa, Insulin resistance, premature adrenarche and a risk of the PCOS. Trends Endocrinol. Metab. 9, 72–77 (1998)

    Article  PubMed  CAS  Google Scholar 

  23. F. Ovalle, R. Azziz, Insulin resistance, polycystic ovary syndrome and type 2 diabetes mellitus. Fertil. Steril. 77, 1095–1105 (2002)

    Article  PubMed  Google Scholar 

  24. J. Kusari, Y. Takata, E. Hatada, G. Freidenberg, O. Kolterman, J.M. Olefsky, Insulin resistance and diabetes due to different mutations in the tyrosine kinase domain of both insulin receptor gene alleles. J. Biol. Chem. 266, 5260–5267 (1991)

    PubMed  CAS  Google Scholar 

  25. A. Dunaif, Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr. Rev. 18, 774–800 (1997)

    Article  PubMed  CAS  Google Scholar 

  26. B.O. Yildiz, O. Gedik, Assessment of glucose intolerance and insulin sensitivity in polycystic ovary syndrome. Reprod. Biomed. Online 8, 649–656 (2004)

    Article  PubMed  CAS  Google Scholar 

  27. A.M. Venkatesan, A. Dunaif, A. Corbould, Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog. Horm. Res. 56, 295–308 (2001)

    Article  PubMed  CAS  Google Scholar 

  28. R. Gonzalez, A. Tiwari, S. Unniappan, Pancreatic beta cells colocalize insulin and pronesfatin immunoreactivity in rodents. Biochem. Biophys. Res. Commun. 381, 643–648 (2009)

    Article  PubMed  CAS  Google Scholar 

  29. M. Nakata, K. Manaka, S. Yamamoto, M. Mori, T. Yada, Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca(2+) influx through L-type channels in mouse islet β-cells. Endocr. J. 58, 305–313 (2011)

    Article  PubMed  CAS  Google Scholar 

  30. V.L. Nelson, K.N. Qin, R.L. Rosenfield, J.R. Wood, T.M. Penning, R.S. Legro, J.F. Strauss III, J.M. McAllister, The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 86, 5925–5933 (2001)

    Article  PubMed  CAS  Google Scholar 

  31. R. Nahum, K.J. Thong, S.G. Hillier, Metabolic regulation of androgen production by human thecal cells in vitro. Hum. Reprod. 10, 75–81 (1995)

    Article  PubMed  CAS  Google Scholar 

  32. H. Shimizu, S. Oh, S. Okada, M. Mori, Nesfatin-1: an overview and future clinical application. Endocr. J. 56, 537–543 (2009)

    Article  PubMed  CAS  Google Scholar 

  33. D.S. Guzick, R. Wing, D. Smith, S.L. Berga, S.J. Winters, Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil. Steril. 61, 598–604 (1994)

    PubMed  CAS  Google Scholar 

  34. R.J. Norman, M.J. Davies, J. Lord, L.J. Moran, The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol. Metab. 13, 251–257 (2002)

    Article  PubMed  CAS  Google Scholar 

  35. B.K. Tan, M. Hallschmid, W. Kern, H. Lehnert, H.S. Randeva, Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans: evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment. J. Clin. Endocrinol. Metab. 96, E669–E673 (2011)

    Article  PubMed  CAS  Google Scholar 

  36. M. Ari, O.H. Ozturk, Y. Bez, S. Oktar, D. Erduran, High plasma nesfatin-1 level in patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 497–500 (2011)

    Article  PubMed  CAS  Google Scholar 

  37. M. Ramanjaneya, J. Chen, J.E. Brown, G. Tripathi, M. Hallschmid, S. Patel, W. Kern, E.W. Hillhouse, H. Lehnert, B.K. Tan, H.S. Randeva, Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology 151, 3169–3180 (2010)

    Article  PubMed  CAS  Google Scholar 

  38. Z. Zhang, L. Li, M. Yang, H. Liu, G. Boden, G. Yang, Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 120, 91–95 (2012)

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors like to extend their thanks to FUBAP for their financial support (project number 1889). And also their heartfelt thanks and never ending admiration to Harry Miller for his editing this manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Firat University Hospital, Elazig, Turkey

    Rulin Deniz, Bilgin Gurates, Husnu Celik, Yakup Baykus & Sami Gungor

  2. Department of Medical Biochemistry and Clinical Biochemistry, Firat Hormones Research Group, Firat University Hospital, 23119, Elazig, Turkey

    Suleyman Aydin & Zekiye Catak

  3. Department of Nutrition and Dietetics, Erzincan University, Erzincan, Turkey

    İbrahim Sahin

  4. Department of Nutrition and Dietetics, Bitlis Eren University, Bitlis, Turkey

    Aziz Aksoy

  5. Department of Biological Science, Firat University, Elazig, Turkey

    Cihan Citil

Authors
  1. Rulin Deniz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bilgin Gurates
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Suleyman Aydin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Husnu Celik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. İbrahim Sahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yakup Baykus
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zekiye Catak
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Aziz Aksoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Cihan Citil
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sami Gungor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Suleyman Aydin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deniz, R., Gurates, B., Aydin, S. et al. Nesfatin-1 and other hormone alterations in polycystic ovary syndrome. Endocrine 42, 694–699 (2012). https://doi.org/10.1007/s12020-012-9638-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-012-9638-7

Keywords

Search

Navigation